Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

730
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
730

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Future mercury emissions from coal-fired power plants in China under dual-carbon targets: An emission-driven sensitivity assessment integrating machine learning and GEOS-Chem modeling.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Polysaccharide-Based Encapsulation of Microbes for Enhanced Microbial Therapy.

Polymer science & technology (Washington, D.C.)·2026
Same author

Comprehensive Analysis of the TLP Gene Family in Pine and Functional Implications in Response to Pine Wood Nematode Infection.

Biology·2026
Same author

Insect Odorant Receptors: From Structure and Evolution to Mechanism and Application.

Insects·2026
Same author

Oral delivery of enterocyte-mimetic butyrate-loaded nanoparticles repairs the gut barrier and inhibits growth of digestive system tumors.

Nature communications·2026
Same author

Combating oxygen toxicity through antioxidants during anammox granular sludge preservation and mechanistic insights.

Bioresource technology·2026

Related Experiment Video

Updated: Oct 15, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.6K

Polydopamine Nanoparticle-Mediated Dopaminergic Immunoregulation in Colitis.

Juanjuan Li1, Weiliang Hou1, Sisi Lin1

  • 1State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|October 29, 2021
PubMed
Summary

This study introduces a novel dopaminergic nanoparticular immunosuppressant (PDNI) that effectively suppresses immune overactivation and inflammation. Combining PDNI with gut bacteria shows enhanced therapeutic potential for inflammatory diseases like colitis.

Keywords:
dopaminergicgut microbiotaimmunoregulationinflammatory bowel diseaseoral probiotic

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.9K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K

Related Experiment Videos

Last Updated: Oct 15, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.6K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.9K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K

Area of Science:

  • Immunology
  • Nanotechnology
  • Microbiology

Background:

  • Current immunosuppressive agents have limitations in efficiency and cause off-target toxicities.
  • Hyperactive immune responses contribute to inflammatory diseases.

Purpose of the Study:

  • To develop a novel immunosuppressant using the dopaminergic system.
  • To evaluate the efficacy of a polydopamine nanoparticular immunosuppressant (PDNI) alone and in combination with gut microbiota modulation for treating inflammation.

Main Methods:

  • Synthesized polydopamine nanoparticles (PDNI) to modulate T cell responses and dendritic cell activation.
  • Combined PDNI with beneficial bacteria for oral delivery to modulate gut microbiota.
  • Tested the therapeutic efficacy in murine models of colitis.

Main Results:

  • PDNI stimulated regulatory T (Treg) cells and inhibited T helper 1 (Th1), Th2, and Th17 cells.
  • PDNI inhibited dendritic cell activation, increasing the Treg/Th17 ratio.
  • The combination therapy demonstrated superior efficacy compared to aminosalicylic acid in colitis models.

Conclusions:

  • The dopaminergic system offers a new approach for immune intervention.
  • PDNI combined with gut microbiota modulation is a promising therapeutic strategy for inflammatory diseases.